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A B S T R A C T
Purpose: There is a shortfall of suitably powered studies to provide evidence for safe prescribing of AEDs
to people with Intellectual Disability (ID). We report clinically useful information on differences in
response to Perampanel (PER) adjunctive treatment for refractory epilepsy between ID sub-groups and
general population from the UK Ep-ID Research Register.
Method: Pooled retrospective case notes data of consented people with epilepsy (PWE) prescribed PER
from 6 UK centres was classiﬁed as per WHO guidance into groups of moderate -profound ID, mild ID and
General population. Demographics, concomitant AEDs, starting and maximum dosage, exposure length,
adverse effects, dropout rates, seizure type and frequency were collected. Group differences were
reported as odds ratios estimated from univariable logistic regression models.
Results: Of the 144 PWE (General population 71, Mild ID 48, Moderate to profound ID 48) examined the
association between withdrawal and ID type was marginally statistically signiﬁcant (p = 0.07). Moderate
to profound ID PWE were less likely to come off PER compared to mild ID (OR = 0.19, CI = 0.04–0.92,
p = 0.04). Differences in mental health side effects by groups was marginally statistically signiﬁcant
(p = 0.06). Over 50% seizure improvement was seen in 11% of General population, 24% mild ID and 26%
Moderate to profound ID.
Conclusions: PER seems safe in PWE with ID. It is better tolerated by PWE with Moderate to profound ID
than PWE with higher functioning. Caution is advised when history of mental health problems is present.
The standardised approach of the Ep-ID register UK used conﬁrms that responses to AEDs by different ID
groups vary between themselves and General population.
© 2017 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Intellectual Disability (ID) is the incomplete development of
cognition and is characterized by impairment of skills manifested
during the developmental period, which contribute to the overall
level of intelligence, i.e. cognitive, language, motor, and social* Corresponding author at: Chygovenck, Three milestone industrial estate, Truro,
Cornwall TR4 9LD, UK.
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creativecommons.org/licenses/by-nc-nd/4.0/).abilities [1]. Levels of severity of ID are stratiﬁed into mild (IQ of
50–69), moderate (35–49), severe (20–34), and profound (<20)
[1]. Amongst those with ID about 85% have a mild condition, 10%
moderate, 4% severe and about 2% profound ID [2].
Life expectancy is reduced in people with moderate or higher
degree of ID with standardized mortality rates of around 3 [3].
There is also higher mental health [4] and physical comorbidity [5]
in ID populations as compared to the general population.
Epilepsy and ID are associated with a range of pathological
processes [6]. The prevalence of epilepsy in people with ID isAssociation. This is an open access article under the CC BY-NC-ND license (http://
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ID it is around 10% compared to 30% to moderate to profound ID
[9]. Most people with ID and epilepsy respond poorly to anti-
epileptic medications as compared to the general population [8].
Epilepsy in people with ID is associated with increased psycho-
logical and behavioural problems [10], healthcare costs [11],
morbidity [12] and mortality [13] relative to non-ID population.
There are higher rates of side effects [14] and polypharmacy [15] in
the ID population. In England, people with ID are 5 times more
likely to have a potentially avoidable emergency admission to
hospital [16]. Epileptic seizures are the most frequent factor
accounting for approximately 6000 admissions a year, equivalent
to 40% of all avoidable emergency admissions in adults with ID
[16]. As Antiepileptic drugs (AEDs) are the mainstay of epilepsy
treatment to prevent avoidable harm in this vulnerable group it is
important to ascertain the most appropriate and relevant drug
therapies for this group. There is currently little evidence to inform
on prescribing AEDs in people with epilepsy and ID [17].
Perampanel (PER) is licensed for use as an adjuvant in refractory
focal epilepsy [18,19]. A recent study [20] in people with ID has
shown behavioural side effects were present in 40.3%. Based on
dose related side effects such as aggression seen in 1–3% and
irritability 4–12% of people it has been suggested that its use in
people with psychiatric conditions, behavioural problems and ID
be considered cautiously [19].
A multicentre study [21] adults with refractory epilepsy
prescribed PER with a subgroup analysis of people with ID showed
no difference in dropout rates and efﬁcacy to general population
and noted similar side effects including psychiatric and behav-
ioural issues. Differences were noted in titration speeds in the two
populations. This study however did not, deﬁne ‘ID’, validate the ID
diagnosis or stratify people into recognized subgroups. This is
important given the clinical differences in presentation of those
with mild versus moderate to profound ID as this would help
deﬁne better person centred treatment in this population.
The UK Ep ID Research Register [17] was created in 2015 to
collect data on efﬁcacy and safety in people with epilepsy and ID
compared to individuals with IQ >70 for newer AED (licensed after
1999). Those with ID are divided into 2 groups i.e. mild ID and
‘moderate to profound ID’ based on the rationale in Appendix 1 in
Supplementary Material. The Register has Ethics Approval (refer-
ence: 14/SC/1270) for data collection and is National Institute of
Health Research (NIHR) UK adopted with seven UK sites currently
afﬁliated and recruiting. The Register is modelled after the UK
Epilepsy and Pregnancy Register that was created for women of
childbearing age who have epilepsy and has provided valuable
longitudinal results on the effects of AEDs in a little studied
population. Similarly people with ID form a signiﬁcant minority in
both epilepsy populations in general and treatment resistant
populations in particular they are not included for any systematic
trails when a molecule is licensed. Any prescribing issues are by
personal experience, peer feedback and imposition of evidence
from general population. To address this gap and provide better
quality real world prescribing guidance the Ep-ID Research
Register was formed. The UK Ep-ID Register has 10 years ethics
and similar to the current study on PER would look longitudinally
at outcomes of other commonly used AED molecules in due course.
2. Methods
Data was obtained from 6 sites. All adults prescribed PER at the
sites at any point (current or withdrawn) prior to 03/2015 and
having had at least 1 follow up post PER commencement were sent
a letter by their attending physician requesting consent to be
contacted. Those who agreed were then contacted by a researcher
who went through the informed consent process. For those withID, the consenting process included providing ‘easy read’ study
information and specially developed consent forms. When one was
deemed not able to provide informed consent a family member or a
carer could assent. Those on treatment for less than a year or on
monotherapy were excluded. All participants were from the
community who attended outpatients at their respective centres.
Where a patient dropped out due to side effects prior the ﬁrst
follow up the contact made to notify was accepted as the ‘follow
up’.
Data was obtained for those consenting or had assented by
reviewing case notes and these were recorded. Case notes were
reviewed for a period of up to 15 months starting with 3 months
prior to commencement (baseline), 3 months post commence-
ment and then 6 months and 12 months. Endpoint was deﬁned as
either 1 year if the individual continued with PER treatment or
when the drug was withdrawn. Withdrawal rates of PER were
estimated as the proportion of people who discontinued PER
within the ﬁrst year.
Demographics data, seizure type, concomitant AEDs, starting
and maximum dosage of PER, length of exposure, adverse effects,
dropout rates and seizure frequency were collected. Duration of
epilepsy was ascertained in intervals of 5 years. Seizure frequency
was recorded as monthly numbers but consolidated into%
improvement from baseline in blocks of 3 months and results
between baseline and endpoint compared.
Outcomes following treatment were deﬁned as worsening or no
improvement, greater than 25%, 50%, 75% improvement in seizures
based on the difference in seizures at endpoint compared to
baseline. Seizure freedom was terminal remission at end point.
No reduction or seizure aggravation was based either on
numerically recorded frequencies or on clinical impression.
Participant’s health proﬁle was requested from their primary
care physician or a discussion took place with a professional at the
practice to collect relevant information to classify ID. All primary
care practices in the UK are expected to have a record of patients
who have been ‘statemented’ or have a diagnosis of Learning or
Intellectual disability as it is a NHS Employers Quality Outcome
Framework factor identiﬁed as “The contractor establishes and
maintains a register of patients with learning disabilities”. The
health proﬁle also contains a list of nature and degree of ID, co-
morbidities, mental and physical deﬁcits. Where identiﬁed pre-
existing conditions were divided into mental and physical co-
morbidity. Major mental health conditions recorded on the proﬁle
were counted. These included Depression (including suicidal
ideation), Anxiety, Psychosis, Pervasive Developmental Disorders
such as Autism, Attention Deﬁcit Hyperactivity Disorder etc.
Medical conditions were predominantly pre-existing chronic
conditions such as neuromuscular disorders such as cerebral
palsy, metabolic syndromes such as diabetes, respiratory issues
such as Chronic Obstructive Pulmonary Disease, Asthma and other
neurological conditions such as stroke. Where the degree of ID was
not speciﬁed two ID specialists reviewed the proﬁle independently
and identiﬁed best ﬁt. No conﬂict was found in classifying ID into
the two groups. Those not on the primary care ID Register was
considered suitable for the ‘general’ group.
Analysis was undertaken a year after the cut-off date to give full
opportunity for all to have had a year of PER. Fisher’s exact test was
used to test for univariate associations between outcomes
(withdrawal, efﬁcacy, adverse events) and ID group (normal/mild
ID/moderate to profound ID). Differences between ID groups were
reported as odds ratios estimated from univariable logistic
regression models. Age and gender were added to these models
as explanatory factors and the results reported if the adjusted
model provided a better ﬁt to the data. The threshold for statistical
signiﬁcance was p = 0.05. Associations with 0.05  p < 0.1 were
reported as marginally statistically signiﬁcant.
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The sample size of n = 71 patients without ID and n = 25 patients
with moderate to profound ID provides 80% power at a signiﬁcance
level of 5% to detect a group difference in drop-out rates of 30%,
assuming a rate of 50% in the non-ID group. Although the study was
adequately powered to detect large effect sizes, difﬁculties in
recruiting sufﬁcient patients with moderate to profound ID meant
that the study was underpowered to detect small to moderate
effect sizes that could still have clinical implications. By pooling
together all ID patients, the study would be powered to detect a
smaller difference in drop out rates of 23%.
3. Results
Of the 279 people originally approached 259 responded of
whom 152 were fully consented and 144 found eligible. Eight did
not satisfy criteria and were excluded. A signiﬁcant proportion of
the remaining 107 when contacted were willing to participate but
did not post back the signed consent forms even when reminded.
There are 71 people from general population (37 females), 48
with Mild ID (26 females) and 25 with moderate to profound ID (16
males). Age ranged between 20 and 76 years old (mean 44), with
Mild ID 23–76 years (mean 48) and the moderate -profound ID 24–
63 years (mean 39). Chronic medical conditions were present in
34% and concurrent mental health problems in 13%. Table 1
provides group speciﬁc baseline clinical data including seizure
frequencies by sub groups.
Ninety nine participants of the 144 had epilepsy for over 15
years including 50/71 of general population, 34/48 in Mild and 15/
25 in moderate to profound groups (Fig. 1). Mean number of
concomitant AEDs was 2.8 for general population, 3.8 for mild ID
and 4.1 for moderate to profound ID.
The starting dose of PER was 2 mg per day in all cases. Doses
were compared after the initial 3 month period of commencement
and at the endpoint (Table 2). At 3 month, 69% of the general
population had higher than 2 mg/day doses (mean dose 4.89 mg/
day after 3 months of commencement, median 4.5 mg/d) but only
36% and 39% of the mild and moderate to profound groups (mean
doses for both groups 3.3 mg/day and median doses 2 mg/d after 3
months of commencement) had moved to a higher dose. The
general group had a total mean dose of 6.63 mg/day versus
5.82 mg/day for mild ID and 4.96 mg/day for moderate to profoundTable 1
Clinical features of patients that underwent PER treatment and study group.
Number (%) No ID Mild Moderate to profound
Age
<40 54 (38%) 21 21 12
40–60 68 (47%) 34 23 11
60+ 20 (14%) 16 3 1
Missing data 2 (1%) 0 1 1
Sex
Male 72 (50%) 34 22 16
Female 71 (50%) 37 26 9
Missing data 0 0 0 0
Chronic medical condition
Yes 92 (64%) 46 30 16
No 47 (33%) 25 13 9
Missing data 5 (3%) 0 5 0
Mental health comorbidity (other than ID)
Yes 19 (13%) 8 10 1
No 125 (87%) 63 38 24
Missing data 0 0 0 0
Seizure Types
Generalised 68 27 (38% 27 (56%) 14 (56%)
Focal 73 41 (58%) 21 (44%) 11 (44%)
Both 3 3 (4%) 0 0ID. Median ﬁnal doses were 6, 6 and 4 mg/day for general, mild and
moderate to profound groups respectively. The mean increases in
doses from starting to endpoint in the period of exposure of up to
1 year or drop out were 2.52 mg/day in the mild ID group compared
to general 1.84 mg/day and moderate to profound of 1.65 mg/day.
The median increases were 2 mg/d in all 3 groups.
The association between withdrawal and ID type was margin-
ally statistically signiﬁcant (Table 2, p = 0.07, Fisher’s exact test).
People with moderate to profound ID were less likely to come off
PER compared to patients with mild ID (OR = 0.19, CI = 0.04–0.92,
p = 0.04). There was no difference in withdrawal rates between the
general population and patients with mild ID (p = 0.25).
All adverse events (AEs) were divided into mental and physical
health sets for each subgroup (Table 2). All AEs were populated as
identiﬁed speciﬁc to PER. There was marginally statistically
signiﬁcant evidence of differences in mental health side effects
by ID group (p = 0.06, Fisher’s exact test) but no such differences
were seen for physical side-effects (p = 0.33, Fisher’s exact test).
The risk of mental health side effects was increased in the
moderate to profound ID group relative to the general population
with epilepsy (OR = 4.2, CI = 1.1–15.2, p = 0.03) but not in the mild ID
group relative to the general population (OR = 2.6, CI = 0.8–8.6,
p = 0.11). The number of recorded AEs in each group was similar
(Table 3). There were reported AEs of 32% in the group without ID,
33% in those with mild ID, and 28% in those with moderate to
Profound ID. When combining the general population and ID
groups, there was a univariate association between a history of co-
morbid mental health/behavioural condition and being more likely
to encounter mental health/behavioural side effects (Table 4,
p = 0.02, Fisher’s exact test). The speciﬁc psychological side effects
observed were challenging behaviour in the form of an occurrence
or increase in aggressive, agitated, disruptive behaviour, depres-
sion, anxiety, mood swings and confusion.
Behavioural/mental health problems across the age there was a
seven fold increase in risk in patients aged less than 30 years of age
relative to patients aged 30 or more (OR = 7.2, CI = 1.5–34.7,
p = 0.01). The main reason for withdrawal in all groups was
intolerable side effects (50- 60%). Psychological side effects
dominated the reasons for withdrawal in the ID groups. Lack of
efﬁcacy led to 20% of withdrawal in the Mild ID group. These and
other factors for all 3 groups are presented in Tables 2 and 3.
None was seizure free. Greater than 50% seizure improvement
was seen in 11% of general population, 24% with mild ID and 26%
with moderate to profound ID (Tables 2 and 3). These differences
were not statistically signiﬁcant (p = 0.11, Fisher’s exact test). No
improvement was noted in 79% of general, 53% of mild ID and 48%
of moderate to profound ID. One person in group had seizure
aggravation.
4. Discussion
We present a pragmatic real world observational survey of PER
retention in a cohort of people with and without ID. The strengths
include robust case selection and deﬁned ID criteria. People with
ID, their families and carers seem more amenable to participate in
research especially into conditions where ID is involved possibly
due to paucity of evidence and previous opportunities. This is
highlighted by our high uptake of people with ID. There are several
observations of interest.
Firstly, there are differences between people with mild ID and
moderate to profound ID in terms of drop-out rates and efﬁcacy,
although these did not reach deﬁnite statistically signiﬁcance.
Secondly, it appears fewer people with moderate to profound ID
stopped PER even though similar side effect rates were reported.
This may be because some side effects (such as dizziness) were not
detected due to the communication problems these people
Fig. 1. Duration of Seizures in relation to individual groups.
Table 2
Outcomes of the study.
All participants No ID Mild ID Moderate to profound ID
Maximum dose achieved at 3 months and overall titration proﬁle
2 mg 64 (44%) 22 (31%) 28 (58%) 14 (56%)
>2 mg 73 (51%) 48 (68%) 16 (33%) 9 (36%)
Missing data 7 (5%) 1 (1%) 4 (8%) 2 (8%)
Mean dose 1st 3 months 4.1 4.89 3.30 3.30
Mean max dose 6.63 5.82 4.96
range 2–12 2–12 2 10 2–10
Dropout rates
Yes 32 (23%) 15 (21%) 15 (31%) 2 (8%)
No 110 (77%) 54 (76%) 33 (69%) 23 (92%)
Missing data 2 (0%) 2 (3%) 0 0
Frequency of physical side effects
Yes 39 19 (27%) 16 (33%) 4 (16%)
No 105 52 (73%) 32 (67%) 21 (84%)
Frequency of mental side effects
Yes 19 5 (7%) 8 (17%) 6 (24%)
No 125 66 (93%) 40 (83%) 19 (76%)
Reasons identiﬁed for coming off PER
Increased seizure frequency 7 4 2 1
Intolerable side-effects 18 8 9 1
Lack of efﬁcacy 3 0 3 0
Other 4 3 1 0
Increased seizure frequency 7 4 2 1
Efﬁcacy
No change 90 (63%) 55 (79%) 24 (53%) 11 (48%)
25% improvement 21 (15%) 6 (9%) 9 (20%) 6 (26%)
50% improvement 20 (14%) 6 (9%) 9 (20%) 5 (22%)
75% improvement 5 (3%) 2 (2%) 2 (4%) 1 (4%)
Worsening 2 (1%) 1 (1%) 1 (2%) 0 (0%)
Missing data 6 (4%) 1 3 2
Table 3
Summary of efﬁcacy and tolerability data for treatment with PER by ID group.
Responder rate (>50% reduction in seizures) Retention rate at 1 year Adverse events
Overall 18% 77% All AEs = 32%
Dizziness = 7.6%
Memory problems = 6.9%
Increased seizures = 6.9%
Confusion = 4.2%
Behavioural disturbance = 3.5%
Sedation = 3.5%
No ID 11% 78% All AEs = 32%
Mild ID 24% 69% All AEs = 33%
Moderate to profound ID 26% 92% All AEs = 28%
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Table 4
Association of mental health condition history and mental health side effects to PER.
History of comorbid mental health conditions Mental health side-effects
Yes No
Yes 6 (32%) 13 (68%)
No 13 (10%) 112 (90%)
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group. There was a greater drop-out in people with mild ID. Side
effects were similar to the comparison groups, but it may be that
known side effects of PER, are less tolerated in this group. The ‘mild
ID’ population is vulnerable to a high degree of suggestibility and
known to present with more ‘attention seeking health conditions’
[22]. This might have resulted in a lower threshold to report effects
compared to the general population and those with more profound
ID, although this remains a speculation. Attention to the way
communication of side effects is undertaken and how it is explored
when concerns arise in this group may help clarify this.
Thirdly, slower titration as shown in the moderate -profound ID
population appears to facilitate better retention of medication and
our study suggests that outcomes were better with treatment
persistence.
While it’s likely that minor side effects go unnoticed or non-
communicated in the moderate to profound population it raises
the issue of whether people with epilepsy or their family reporting
minor side effects and wishing the AED to be withdrawn are
counselled of the potential harm of losing a viable therapeutic
option. Stopping drugs need to be deliberated in context of the
increased risk of premature mortality in people with treatment
resistant epilepsy [23,24]. Person centred and ﬂexible strategies
with the individual as the partner may pay dividends in helping
better retention. This includes considering slower titration of
medication [25], reducing to the previous suitable dose and
medication management education.
We compared our ﬁndings to two recent PER studies [19,20,21].
Our overall ﬁndings co-relate to the ﬁndings of these studies. Two
of the studies [20] examined the effects of PER in a subpopulation
of ID. One study [21], however, made no distinction between mild
and moderate to profound levels of ID and drop-out rates after 12
months were far higher at 62% for ID and 52% for non-ID groups.
Efﬁcacy was much better for both groups at 43% having more than
50% improvement in seizure frequency. A recent study [20] which
speciﬁcally looking at populations if ID did not compare with
general population. Their ID sample was less to our ID sample size
but comparable. The seizure reduction rates of around 50%, better
retention rates by more severe ID patients and the dosing were
comparable to our study results.
Our observations suggest that PER seems safe in people with ID.
It appears to be better tolerated by people with moderate to
profound ID than in people with higher functioning, although this
might be due to communication difﬁculties. Moderate -profound
group efﬁcacy may be superior to the other 2 groups, whether due
to persistence in use or inherent better efﬁcacy.
PER should be used with caution and care in people who has a
past history of mental health problems and behaviour disturbances
particularly if under the age of 30 years.
We acknowledge several limitations. Firstly, people were
retrospectively consented, which might introduce a bias towards
people with a more favourable response. Seizure frequency and
side effects data were retrospectively collected from medical notes
and might thus introduce bias towards the most recent experience
of the person or their caregiver. The numbers in our treatment
groups may also introduce a type 2 error of not ﬁnding statistical
differences when they may be present. Although the study didyield some interesting ﬁndings we view our ﬁndings as provisional
and requiring replication before mandating a change in clinical
practice because of the borderline statistical signiﬁcance and the
potential for bias in retrospective analysis of case notes. Further the
study has not looked into the number of con-commitment
medication, daily dosing and dose dependency inﬂuences on side
effects.
The study uses a standardised approach of the Ep-ID register
UK. It conﬁrms our hypothesis that the response to AEDs of people
of different ID groups varies between themselves and the general
population.
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